🇺🇸 FDA

Company profile · Sponsor

CITIUS

CITIUS ONCOLOGY, INC.

CTOR · NYSE pharma CRANFORD, NJ, USA
Pipeline
3
Drugs
0
Patents
0

Quick answer

CITIUS (CTOR) is a pharma company. headquartered in CRANFORD, NJ, USA. listed on NYSE. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker CTOR
Exchange NYSE
Company type pharma
Headquarters CRANFORD, NJ, USA
SEC CIK 0001851484

Pipeline (3)

Search pipeline →

  1. E7777 9 mcg/kg

    CITIUS

    Persistent or Recurrent Cutaneous T-Cell Lymphoma

    phase 3 small molecule completed

    1 trial

  2. Hydrocortisone acetate and lidocaine hydrochloride

    CITIUS

    Hemorrhoids

    phase 2 small molecule completed

    1 trial

  3. Monad 1

    CITIUS

    Hemorrhoids

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is CITIUS?

CITIUS (CTOR) is a pharma company. headquartered in CRANFORD, NJ, USA. listed on NYSE. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does CITIUS sponsor?

We track 3 ClinicalTrials.gov-linked programs for CITIUS, including E7777 9 mcg/kg and 2 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does CITIUS company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.